6月29日，复星医药（600196/02196）发布公告，控股子公司河北万邦复临药业有限公司的芍药甘草汤颗粒药品注册申请已获国家药品监督管理局批准。 该药品为中药3.1类，剂型为颗粒剂，每袋相当于饮片27.60g。截至2026年5月，该药品的累计研发投入约为591万元（未经审计）。 2026年一季度，复星医药实现收入100.73亿元，归母净利润8.71亿元。（文章来源：财中社）
Source Link6月29日，复星医药（600196/02196）发布公告，控股子公司河北万邦复临药业有限公司的芍药甘草汤颗粒药品注册申请已获国家药品监督管理局批准。 该药品为中药3.1类，剂型为颗粒剂，每袋相当于饮片27.60g。截至2026年5月，该药品的累计研发投入约为591万元（未经审计）。 2026年一季度，复星医药实现收入100.73亿元，归母净利润8.71亿元。（文章来源：财中社）
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.